CenTrial Logo

Clinical Trial Shows Significant Reduction in Myopia Incidence with Atropine Eyedrops


Trial shows atropine eyedrops reduce myopia in children

The use of low-concentration atropine eyedrops may significantly reduce the incidence of myopia in children, according to a randomized clinical trial. The trial involved 474 nonmyopic children aged 4 to 9 years and lasted for two years.


Myopia, also known as nearsightedness, is a common eye condition that affects many children worldwide. It is characterized by a refractive error that causes distant objects to appear blurry, while nearby objects remain clear. If left untreated, myopia can progress to high myopia, a more severe form of the condition that is associated with an increased risk of eye diseases such as glaucoma, cataracts, and retinal detachment.

Clinical trial

The study aimed to evaluate the efficacy of low-concentration atropine eyedrops at 0.05% and 0.01% concentration for delaying the onset of myopia. Participants were randomly assigned to three groups: the 0.05% atropine group, the 0.01% atropine group, and the placebo group. They were instructed to apply the eyedrops once nightly in both eyes for two years.

The results showed that the 0.05% atropine group had a significantly lower incidence of myopia compared to the placebo group. The 2-year cumulative incidence of myopia in the 0.05% atropine group was 28.4%, while that of the placebo group was 53.0%. The difference between the two groups was statistically significant.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me

Moreover, the percentage of participants with fast myopic shift was also lower in the 0.05% atropine group compared to the placebo group. Fast myopic shift is a measure of the speed at which myopia progresses, and it is an important predictor of high myopia later in life. The 0.05% atropine group had a fast myopic shift percentage of 25.0%, while that of the placebo group was 53.9%.

The 0.01% atropine group did not show a significant difference in myopia incidence or fast myopic shift percentage compared to the placebo group. However, the difference between the 0.05% atropine group and the 0.01% atropine group was statistically significant.

It is important to note that further research is needed to replicate these findings and to understand whether the use of atropine represents a delay or prevention of myopia. Additionally, longer-term safety should be assessed before atropine is widely used as a treatment for myopia.


The use of low-concentration atropine eyedrops may be an effective way to reduce the incidence of myopia in children. However, more research is needed to confirm these findings and to assess the long-term safety of this treatment. Parents should consult with their eye doctor to determine the best course of action for their child's eye health.

JAMA, Feb-14-23

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Without participants there can be no clinical trials.
Without clinical trials there will be no new treatments.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.